Lv Xueyan, Wang Dongmei, Zou Xiangni
Heilongjiang University of Chinese Medicine, Harbin, China.
First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Medicine (Baltimore). 2025 Jul 25;104(30):e43625. doi: 10.1097/MD.0000000000043625.
Anemia is a common and widely influential public health problem worldwide. The objective was to conduct a comprehensive and in-depth systematic evaluation of the therapeutic efficacy of Guipi Decoction as an adjuvant treatment for patients with anemia and to offer new ideas for the clinical treatment of anemia.
A comprehensive and systematic literature search was meticulously executed across multiple authoritative databases, including CNKI, Wanfang, VIP, EMBase, Scopus, Web of Science, PubMed, and the Cochrane Library. The search was designed to identify all relevant randomized controlled trials that investigated the application of Guipi Decoction as an adjuvant therapy for Anemia patients. Considering that 1 researcher had written article of this kind in 2020, so the time frame of the search spanned from January 2020 to January 2025. Two independent reviewers selected eligible trials, extracted data, and assessed methodological quality using predefined criteria. Meta-analysis was performed using the standardized software RevMan 5.3.
A total of 13 studies were included in the final analysis, involving a cumulative sample size of 954 participants. These participants were randomly allocated to the experimental group and the control group. Pretreatment physiological parameters were comparable between the 2 groups, with no statistically significant differences, indicating a balanced randomization. Posttreatment, the experimental group demonstrated significantly better outcomes across multiple clinically relevant endpoints compared to the control group. The indicators include the effective rate, adverse event rate, hemoglobin, red blood cell, serum iron, serum ferritin, and hematocrit. For the experimental group, there are statistically significant differences in various indicators before and after treatment. At the same time, when compared with the indicators of the control group after treatment, the outcome indicators of the experimental group show a better therapeutic effect, and the differences are statistically significant. This can strongly prove that Guipi Decoction has a definite therapeutic effect on treating anemia.
Guipi Decoction can effectively relieve symptoms in anemia patients and reduce risk indicators. It is worthy of further research and promotion.
贫血是全球常见且影响广泛的公共卫生问题。目的是对归脾汤作为贫血患者辅助治疗的疗效进行全面深入的系统评价，为贫血的临床治疗提供新思路。
在多个权威数据库中精心进行全面系统的文献检索，包括中国知网、万方、维普、EMBase、Scopus、Web of Science、PubMed和Cochrane图书馆。检索旨在识别所有研究归脾汤作为贫血患者辅助治疗应用的相关随机对照试验。鉴于2020年有1名研究人员撰写了此类文章，因此检索时间范围为2020年1月至2025年1月。两名独立评审员选择符合条件的试验，提取数据，并使用预定义标准评估方法学质量。使用标准化软件RevMan 5.3进行荟萃分析。
最终分析共纳入13项研究，累计样本量为954名参与者。这些参与者被随机分配到实验组和对照组。两组治疗前的生理参数具有可比性，无统计学显著差异，表明随机分组均衡。治疗后，与对照组相比，实验组在多个临床相关终点的结果明显更好。指标包括有效率、不良事件发生率、血红蛋白、红细胞、血清铁、血清铁蛋白和血细胞比容。实验组治疗前后各项指标差异有统计学意义。同时，与治疗后对照组的指标相比，实验组的结局指标显示出更好的治疗效果，差异有统计学意义。这有力证明归脾汤治疗贫血有确切疗效。
归脾汤能有效缓解贫血患者症状，降低风险指标。值得进一步研究和推广。
